Exact Sciences Corp - EXAS Company Value to Revenue

exactsciences.com (EXAS) - corporate logo

Despite pressure in the liquid biopsy sector, Exact Sciences attracts leading geneticists due to its strong ethics and R&D investments. The enterprise value-to-revenue multiple helps value the asset regardless of debt, while 6651.19 represents the latest level. Diagnostic efficiency is maintained through external logistics and the outsourcing of IT platforms.

EXAS (Exact Sciences Inc.) Company Value to Revenue history from 11/23/2025 to 04/04/2026

Exact Sciences Inc. - analytical breakdowns and key metrics (EXAS)

- current quotes and average value forecast:
Fundamental company valuation:EXAS (Exact Sciences)
Original product of Cologuard

The selection of high-quality issuers is based on an analysis of multiples that exclude the impact of debt structure on market value. The EV/Sales metric measures the total enterprise value relative to revenue, allowing for an assessment of revenue generation efficiency regardless of leverage. For Exact Sciences (EXAS), whose growth is driven by innovation and inelastic demand, changes in the EV/Sales valuation confirm the fundamental resilience of the business across economic cycles.

Competitor analysis for Exact Sciences

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|RVTY (Revvity Corp) - EV/Sales Multiple|EV/Sales Multiple Bio-Rad Laboratories Inc|Company Value to Revenue NNNN (Anbio Biotechnology)|SHC (Sotera Health Company) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio QuidelOrtho Inc. QDEL|EV/Sales Multiple OPKO Health Inc OPK|CareDx Inc - EV/Sales Multiple|Business Value to Revenue MRVI (Maravai)|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue